TLX.AX Telix (ASX) A$11.32 19 Jan 2026 ahead of earnings: trial readouts
TLX.AX stock traded at A$11.32 on 19 Jan 2026, with the company set to report earnings on 20 Jan 2026. Investors are focused on clinical trial updates and how near-term commercial adoption of Illuccix and Gozellix will affect revenue and margins. Telix Pharmaceuticals Limited (TLX.AX) carries high volatility and biotech-specific binary risk tied to study readouts and regulatory pathways. We examine financial ratios, recent catalysts, and the Meyka AI forecast to show what could move the share price at market open tomorrow.
Earnings spotlight: TLX.AX stock and the Jan 20 earnings report
Telix (TLX.AX) will report after the ASX close on 20 Jan 2026, with markets watching revenue drivers and EPS trends. The company shows EPS A$0.03 and a reported PE of 382.67, highlighting thin near-term earnings versus price. Today’s trading range was A$11.04–A$11.72 on volume 2,201,519 shares, versus an average volume of 1,741,634. Expect commentary on sales uptake and reimbursement progress to be the decisive element in tomorrow’s trade.
Clinical catalysts and recent TLX.AX news
This week Telix announced the first U.S. patient dosed in the BiPASS Phase 3 study for pre-biopsy PSMA-PET imaging, a move that could materially expand the addressable market if successful source. Separately, broader headlines and legal filings have influenced sentiment source. Clinical readouts remain the primary opportunity to re-rate TLX.AX stock.
Valuation and fundamentals for TLX.AX stock
Telix’s balance shows market cap A$3,888,999,240.00, price-to-sales 3.28, price-to-book 9.17, and debt-to-equity 0.99. Revenue per share is A$3.52, and book value per share is A$1.25. The company is improving profitability with net income per share A$0.10 TTM, but valuation metrics remain rich versus healthcare peers, reflecting growth expectations priced into TLX.AX stock.
Technical snapshot and Meyka grade for TLX.AX stock
Technicals show short-term weakness with RSI 29.09 (oversold) and price below the 50-day average A$13.04 and 200-day average A$18.91. Volatility indicators point to a strong trend (ADX 42.99) and an ATR of A$0.49. Meyka AI rates TLX.AX with a score out of 100: 68.47 (Grade B, HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.
Price targets and TLX.AX stock forecast
Meyka AI’s forecast model projects a yearly price of A$13.28, a monthly outlook of A$16.02, and a quarterly figure of A$6.12. Against the current price A$11.32, the yearly forecast implies an upside of 17.30% and the monthly projection implies 41.50%. Analysts and investors should treat these as model-based projections and not guarantees. Suggested scenario targets: conservative A$9.00, base A$13.50, and bullish A$18.00, reflecting trial success and broader commercial uptake.
Risks and opportunities for investors in TLX.AX stock
Key risks include negative trial outcomes, slower-than-expected reimbursement, and legal or regulatory setbacks. Offsetting opportunities are approval expansions, BiPASS success driving pre-biopsy adoption, and commercial rollouts in the U.S. and Japan. Liquidity is moderate with average volume 1,741,634, but price swings have been large year-on-year, so position sizing is important for TLX.AX stock exposure.
Final Thoughts
TLX.AX stock traded at A$11.32 on 19 Jan 2026 as the market waits for the 20 Jan 2026 earnings and management commentary. Clinical catalysts, especially the BiPASS Phase 3 program and adoption of Illuccix/Gozellix, are the primary drivers that could change the company’s revenue trajectory. Valuation metrics such as price-to-sales 3.28 and price-to-book 9.17 reflect high growth expectations but also leave limited margin for disappointment. Meyka AI’s forecast model projects a yearly price of A$13.28, implying ~17.30% upside to current levels, while a monthly scenario shows larger upside if near-term catalysts succeed. Investors should weigh binary clinical risk against potential commercial expansion. Meyka AI, our AI-powered market analysis platform, flags TLX.AX as a hold into earnings for risk-managed exposure and recommends watching trial updates and the earnings call for concrete revenue and reimbursement details. Forecasts are model-based projections and not guarantees.
FAQs
When does Telix (TLX.AX) report earnings?
Telix (TLX.AX) has an earnings announcement scheduled for 20 Jan 2026. Investors should watch revenue guidance, EPS commentary, and clinical readouts discussed on the call.
What is the current price and valuation for TLX.AX stock?
As of 19 Jan 2026 TLX.AX is A$11.32 with a market cap near A$3.89 billion, price-to-sales 3.28, and price-to-book 9.17. Valuation reflects growth expectations.
How does Meyka AI view TLX.AX stock?
Meyka AI rates TLX.AX 68.47 out of 100 (Grade B, HOLD). The grade balances clinical opportunity, sector performance, financial growth, and analyst sentiment. This is informational only.
What are the main catalysts that could move TLX.AX stock?
Key catalysts are the BiPASS Phase 3 results, regulatory approvals, reimbursement decisions, and commercial adoption of Illuccix and Gozellix. Positive trial news could substantially re-rate the stock.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
